Sep 15, 2020 · Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts.

Takeda's pipeline is diverse and dynamic, with first-in-class molecules that address areas of high unmet need. We're committed to accelerating a steady stream of therapies with transformative or curative potential.

Mar 9, 2021 · Under the agreement, Takeda will obtain Maverick’s T-cell engager COBRA™ platform and a broad development portfolio, including Maverick’s lead development candidate TAK-186 (MVC-101) currently in a Phase 1/2 study for the treatment of EGFR-expressing solid tumors, and TAK-280 (MVC-280), which is anticipated to enter the clinic in the ...

Nov 5, 2019 · Under the agreement, Takeda will receive access to MD Anderson’s CAR NK platform and the exclusive rights to develop and commercialize up to four programs, including a CD19-targeted CAR NK-cell therapy and a B-cell maturation antigen …

Feb 2, 2025 · Japanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in 'off-the-shelf' cell therapies for solid tumours and blood cancers.

6 days ago · Takeda has announced a $100 million collaboration with Abingworth to work with GammaDelta Therapeutics, a UK biotech which is pioneering a novel type of T cell therapy.

Takeda’s cell therapy manufacturing facilities foster proactive and deep collaboration between R&D and commercial manufacturing that is critical to developing and delivering next-generation cell therapies faster.

Jan 6, 2025 · The Cell Process Development team operates as the bridge between early discovery and manufacturing by developing large-scale processes for our cell therapy projects. We work closely with our Drug Discovery Units, early CMC, and manufacturing colleagues to produce manufacturing-ready cell therapy processes. Job Description:

Sep 15, 2020 · Japanese drugmaker Takeda has opened a new facility at its research headquarters in Cambridge, Massachusetts to manufacture cancer cell therapies, part of the company’s rapid push into development of the complex treatments.

Mar 12, 2021 · To support Takeda’s focus on cell therapies, we recently broke ground on a new 38,000 square-foot (3,530 square-meter) commercial cell therapy manufacturing facility on our Lexington, Massachusetts, campus. The new $84M facility will be used for the production of oncology and other cell therapies.